1-5 of 5
Rajesh Odedra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Jeremy Karlin, Jasmine Allen, Syed F. Ahmad, Gareth Hughes, Victoria Sheridan, Rajesh Odedra, Paul Farrington, Elaine B. Cadogan, Lucy C. Riches, Antonio Garcia-Trinidad, Andrew G. Thomason, Bhavika Patel, Jennifer Vincent, Alan Lau, Kurt G. Pike, Thomas A. Hunt, Amrita Sule, Nicholas C.K. Valerie, Laura Biddlestone-Thorpe, Jenna Kahn, Jason M. Beckta, Nitai Mukhopadhyay, Bernard Barlaam, Sebastien L. Degorce, Jason Kettle, Nicola Colclough, Joanne Wilson, Aaron Smith, Ian P. Barrett, Li Zheng, Tianwei Zhang, Yingchun Wang, Kan Chen, Martin Pass, Stephen T. Durant, Kristoffer Valerie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (8): 1637–1647.
https://doi.org/10.1158/1535-7163.MCT-17-0975
Published: 31 July 2018
View article titled, Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Open the PDF for Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice in another window
Includes: Multimedia, Supplementary data
Journal Articles

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Nicolas Floc'h, Susan Ashton, Paula Taylor, Dawn Trueman, Emily Harris, Rajesh Odedra, Kim Maratea, Nicola Derbyshire, Jacqueline Caddy, Vivien N. Jacobs, Maureen Hattersley, Shenghua Wen, Nicola J. Curtis, James E. Pilling, Elizabeth J. Pease, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1031–1040.
https://doi.org/10.1158/1535-7163.MCT-16-0580
Published: 01 June 2017
View article titled, Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
Open the PDF for Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles in another window
Includes: Supplementary data
Journal Articles

Abstract C60: Pre-clinical efficacy of the ATR inhibitor AZD6738 in combination with the PARP inhibitor olaparib

Alan Lau, Elaine Brown, Andrew Thomason, Rajesh Odedra, Victoria Sheridan, Elaine Cadogan, Shirlian Xu, Andy Cui, Paul R. Gavine, Mark O'Connor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C60.
https://doi.org/10.1158/1535-7163.TARG-15-C60
Published: 01 December 2015
View article titled, Abstract C60: Pre-clinical efficacy of the ATR inhibitor AZD6738 in combination with the PARP inhibitor olaparib
Journal Articles

Abstract A225: The mTOR kinase inhibitor AZD8055 modulates 18F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG

Heather Keen, Sally‐Ann Ricketts, Juliana Bales, Aoife Shannon, Armelle Logie, Rajesh Odedra, Steve Wedge, Sylvie Guichard
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A225.
https://doi.org/10.1158/1535-7163.TARG-09-A225
Published: 10 December 2009
View article titled, Abstract A225: The mTOR kinase inhibitor AZD8055 modulates <sup>18</sup>F‐FDG uptake <em>in vivo</em> in the human glioma xenograft model U87‐MG
Journal Articles

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

Jeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, Patrizia Sini, Simon P. Heaton, Kirsten E. Mundt, Tim H. Ward, Robert W. Wilkinson, Jim Growcott, Andrew Hughes, Caroline Dive
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 455–463.
https://doi.org/10.1158/1535-7163.MCT-07-2136
Published: 17 March 2008
View article titled, Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity
Open the PDF for Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity in another window